Physician profile
Michael E Debs
NPI 1063486082
$8,552.09
in general payments reported to CMS, 2019-2025
47 companies · $1,233 in 2025
The $1,233 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,127 · 2020: $568 · 2021: $1,321 · 2022: $1,204 · 2023: $1,538 · 2024: $1,561 · 2025: $1,233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,332.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,002.59 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Novo Nordisk INC | $794.23 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $762.03 | 2020-2025 | Vraylar, Ubrelvy, Synthroid |
| Lilly USA, LLC | $538.20 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $526.98 | 2019-2025 | Jardiance, Synjardy |
| Amgen INC. | $506.98 | 2019-2025 | Krystexxa, Repatha, Prolia |
| Pfizer INC. | $453.35 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $388.21 | 2019-2025 | Spravato, Xarelto |
| Novartis Pharmaceuticals Corporation | $348.10 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $301.24 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Abbott Laboratories | $218.11 | 2021-2025 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $213.93 | 2020-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $201.41 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $193.73 | 2019-2025 | Camzyos, Eliquis |
| Astellas Pharma US INC | $191.99 | 2019-2023 | Veozah, Myrbetriq |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $166.64 | 2019-2021 | |
| Glaxosmithkline, LLC. | $164.45 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Biohaven Pharmaceuticals, INC. | $153.00 | 2021 | |
| Lundbeck LLC | $152.16 | 2023-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $147.01 | 2023-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $127.19 | 2019-2021 | |
| Exact Sciences Corporation | $99.31 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.16 | 2019-2024 | Xifaxan, Trulance |
| Allergan, INC. | $76.49 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $73.87 | 2022 | |
| Corcept Therapeutics | $72.56 | 2024-2025 | Korlym |
| Medtronic Vascular, INC. | $72.33 | 2019 | |
| Xeris Pharmaceuticals, INC. | $68.65 | 2022-2025 | Gvoke Hypopen |
| Avanir Pharmaceuticals, INC. | $61.46 | 2019-2022 | |
| Eisai INC. | $38.97 | 2021 | |
| Sumitomo Pharma America, INC. | $37.64 | 2023 | Gemtesa |
| Dexcom, INC. | $36.74 | 2024 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $35.59 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $28.63 | 2023 | Lifevest |
| Melinta Therapeutics, LLC | $27.28 | 2023 | Rezzayo, Orbactiv, Kimyrsa |
| Sanofi Pasteur INC. | $20.09 | 2023 | |
| Pulmonx Corporation | $19.36 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Neurocrine Biosciences, INC. | $19.11 | 2023 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $17.94 | 2022 | |
| Phathom Pharmaceuticals, INC. | $16.77 | 2024 | Voquezna |
| Inspire Medical Systems, INC. | $16.51 | 2025 | Inspire |
| Ultragenyx Pharmaceutical INC. | $15.09 | 2022 | |
| Hikma Pharmaceuticals USA | $14.66 | 2019 | |
| Horizon Therapeutics Plc | $13.66 | 2019 | |
| Ironwood Pharmaceuticals, INC | $13.60 | 2019 | |
| Biogen, INC. | $12.35 | 2020 | |
| Gilead Sciences, INC. | $11.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Debs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.